<DOC>
	<DOCNO>NCT01017159</DOCNO>
	<brief_summary>The purpose study determine whether subcutaneous immunoglobulin give small dos , effective maintain force , patient chronic inflammatory demyelinate polyradiculoneuropathy compare placebo ( saline infusion ) , intravenous immunoglobulin .</brief_summary>
	<brief_title>Subcutaneous Immunoglobulin Treatment Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy ( CIDP )</brief_title>
	<detailed_description>CIDP autoimmune disease peripheral nervous system , respond well treatment intravenous immunoglobulin ( IVIg ) , steroids plasmapheresis . IVIg effective treating patient CIDP , patient need long time maintenance treatment , associate decreased autonomy regular hospital admission . Furthermore many patient complain infusion relate side effect headache , chill fatigue , time problem obtain intravenous entry occlusion vein . There therefore critical need alternative method IVIg treatment . The aim study evaluate efficacy , tolerability safety small dos immunoglobulin administer subcutaneously ( SCIg ) , compare placebo . At time compare efficacy SCIg regular IVIg treatment . We therefore hypothesize , 1 : SCIg well subcutaneous placebo infusion , good IVIg maintain muscle function patient CIDP . 2 : SCIg home treatment safe tolerable . 3 : SCIg home treatment preferred IVIg hospital admission , patient .</detailed_description>
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>All patient typical pure motor CIDP , meet clinical electrophysiological criterion EFNS/PNS certain probable CIDP regular treatment IVIg one neurological department Denmark , eligible study Pregnancy Known cancer disease Severe medical disease Other immuno modulate treatment lowdose steroid ( prednisolone &lt; 25 mg/day ) within last 6 week inclusion Hepatitis B C HIV Breastfeeding Nonresponding treatment intravenous immunoglobulin Known hypersensitivity intravenous immunoglobulin Kiovig Adverse event : Previous moderate headache minor rash day infusion exclusion criterion In case severe adverse effect treatment patient exclude . Moderate mild sideeffects treat analgetics steroid 12 week initial study phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</keyword>
	<keyword>Subcutaneous immunoglobulin</keyword>
</DOC>